Novel drug molecule for the treatment of Cancer Metastasis
First-in-class & Best-in-class Small Molecule Chemokine Pan-Antagonist (CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR9, CXCR4) with a Unique Binding Properties.
- Our novel molecule prevents the metastasis development;*
- Our novel molecule prevents metastasis development in lungs by about 5-7 folds;*
- Our novel molecule completely prevented metastasis development in liver and ribs;*
- No any metastasis have been observed in liver and ribs in all drug doses groups;*
* Oral administration: P.O. in single daily dose.
* Based on in vivo study by 4T1-Luc+ model were performed.
CCR2, CCR5, CCR7 and CXCR4 greatly involved in the formation and development of cancer metastasis.
Several chemokine receptors such as CCR1, CCR3, CCR5 and CCR7 are involved in the “cytokine storm” thus a pan-antagonist that can bind and act simultaneously inhibit multiple chemokine receptors.
One of our molecule acts as an inhibitor of the inflammation and has an effect on CCL2, IL8 and IL17, because CCR2 and most likely CCR4 antagonist are involved.
